Table 3.
Baseline characteristics between patients who resumed systemic treatment and those who did not
| Characteristic | No systemic treatment resumed n = 85 | Resumed systemic treatment n = 150 | p value |
|---|---|---|---|
| Age (years) | 61.7 ± 10.5 | 59.8 ± 11.7 | 0.20 |
| Male Sex | 46 (40.0) | 69 (60.0) | 0.28 |
| Adjusted CCI | 0.49 | ||
| 0 | 7 (28.0) | 18 (72.0) | |
| 1 | 19 (43.2) | 25 (56.8) | |
| 2 | 15 (30.6) | 34 (69.4) | |
| ≥ 3 | 44 (37.6) | 73 (62.4) | |
| Number of daily drugs in current use | 0.75 | ||
| 0 | 11 (42.3) | 15 (57.7) | |
| 1 - 5 | 47 (36.4) | 82 (63.6) | |
| ≥ 5 | 27 (34.2) | 52 (65.8) | |
| Neoplasia, type | 0.03 | ||
| Nonhematologic | 76 (39.4) | 117 (60.6) | |
| Primary topography of nonhematologic tumors | 0.18 | ||
| Digestive tract and digestive glands | 30 (54.5) | 25 (45.5) | |
| Lungs and respiratory tract | 10 (31.3) | 22 (68.8) | |
| Breast | 12 (32.4) | 25 (67.6) | |
| Head and neck | 6 (50.0) | 6 (50.0) | |
| Gynecologic | 2 (18.2) | 9 (81.8) | |
| Others* | 16 (34.8) | 30 (65.2) | |
| Previous antineoplastic treatment | |||
| Curative intent | 15 (21.7) | 54 (78.3) | 0.004 |
| Palliative intent | 70 (42.2) | 96 (57.8) | |
| Time since last treatment (days) | 13.0 [0 - 56] | 12.0 [0 - 56] | 0.34 |
| > 1 previous treatment lines | 53 (40.8) | 77 (59.2) | 0.13 |
| Time since diagnosis (months) | 18.0 [0 - 150] | 14.5 [0 - 215] | 0.47 |
| Inpatient admission cause | 0.07 | ||
| Infection | 26 (26.0) | 74 (74.0) | |
| Uncontrolled pain | 11 (40.7) | 16 (59.3) | |
| Respiratory insufficient (not infectious) | 7 (53.8) | 6 (46.2) | |
| Neurologic dysfunction (not infectious) | 2 (25.0) | 6 (75.0) | |
| General status degradation | 4 (50.0) | 4 (50.0) | |
| Other causes† | 35 (44.3) | 44 (55.7) | |
| AOF | 29 (37.7) | 48 (62.3) | 0.77 |
| Discharge patient health status | 0.04 | ||
| Improved | 64 (32.8) | 131 (67.2) | |
| Stable | 18 (50.0) | 18 (50.0) | |
| Worsen | 3 (75.0) | 1 (25.0) |
CCI - Charlson comorbidity index; AOF - acute organ failure.
Malignant neoplasms of mesothelial or soft tissue, malignant neoplasms of male genital organs, malignant neoplasms of urinary tract, malignant neoplasms of skin, malignant neoplasms of thyroid or other endocrine glands, malignant neoplasms of bone and articular cartilage, malignant neoplasms of ill-defined, secondary and unspecified sites, malignant neoplasms of independent (primary) multiple sites. † gastrointestinal disturbances, hemorrhage, hepatic failure, kidney failure, electrolytic disturbances, pancytopenia, cardiac failure or other cardiac causes, cord compression syndrome, mucositis, superior vena cava syndrome, anemia. Results expressed as mean ± standard deviation, n (%) or median [range].